1 / 1

Exocrine Pancreatic Insufficiency Market Insights, Epidemiology and Market Forecast 2030

The estimated Exocrine Pancreatic Insufficiency prevalence in Japan is more than 25 cases per 100,000 with a higher rate in men compared to women.<br>The estimated Exocrine Pancreatic Insufficiency prevalence in the defined German population is 6.4 cases per 100,000 inhabitants.<br>An apparent increase of disease with age is observed from 6.0% in the 50-54 years age group to 15.5% in the 65-69 years age group, and 13.4% in the 70-75 years age group.<br><br>To read more visit: https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market<br>#market #marketresearch #pharmaceutical #PancreaticDisease #exocrine #pancreatic #epi #Exocrinepancreaticinsufficiency <br>

arawat
Télécharger la présentation

Exocrine Pancreatic Insufficiency Market Insights, Epidemiology and Market Forecast 2030

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Exocrine Pancreatic Insufficiency Market Insights, Epidemiology and Market Forecast 2030 Exocrine Pancreatic Insufficiency report Key facts ● In Japan, the estimated Exocrine Pancreatic Insufficiency prevalence is 25 cases per 100,000 with a higher rate in men compared to women. ● In Germany, the estimated Exocrine Pancreatic Insufficiency prevalence is about 6.4 cases per 100,000 inhabitants. ● In 7 major markets, a higher proportion of Exocrine Pancreatic Insufficiency prevalence is observed in males as compared to females. Exocrine Pancreatic Insufficiency report key benefit Delveinsight’s Exocrine Pancreatic Insufficiency comprehensive insight of the Exocrine Pancreatic Insufficiency epidemiology, market insight in the 7 Major markets (i.e. the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) Delveinsight’s Exocrine Pancreatic Insufficiency market report covers current and emerging therapies of Exocrine Pancreatic Insufficiency. Exocrine Pancreatic Insufficiency market report provides a global historical and forecasted market of Exocrine Pancreatic Insufficiency. Exocrine Pancreatic Insufficiency market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Exocrine Pancreatic Insufficiency market. Delveinsight’s Exocrine Pancreatic Insufficiency market report covers potential drugs recently launched in the Exocrine Pancreatic Insufficiency (EPI) market or expected to get launched in the market during the study period 2017-2030. Some of the drugs in the Exocrine Pancreatic Insufficiency treatment includes MS1819, SNSP003, And many others. In the upcoming years, the launch of emerging therapies is expected to significantly impact Exocrine Pancreatic Insufficiency treatment. Some of the key players in the Exocrine Pancreatic Insufficiency market includes AzurRx Biopharma, Synspira Therapeutics and many others. In the coming years, Exocrine Pancreatic Insufficiency (EPI) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance. market report provides a

More Related